MYSTERIOUS: Atea pharmaceuticals - You Need To See This

Atea Pharmaceuticals Q1 Earnings Call Highlights

Atea Pharmaceuticals (NASDAQ:AVIR) said it remains on track for two key Phase 3 hepatitis C readouts in 2026 while advancing a newer hepatitis E program aimed at immunocompromised patients with no approved treatment options. During the company’s first-quarter 2026 earnings call, Chief Executive Off

MarketBeat · May 12

Atea Pharmaceuticals: Q1 Earnings Insights

  Atea Pharmaceuticals (NASDAQ:AVIR) reported its Q1 earnings results on Tuesday, May 10, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

Benzinga · May 10, 2022

Earnings Preview For Atea Pharmaceuticals

Atea Pharmaceuticals (NASDAQ:AVIR) is set to give its latest quarterly earnings report on Tuesday, 2022-05-10. Here's what investors need to know before the announcement. Analysts estimate that Atea Pharmaceuticals will report an earnings per share (EPS) of $-0.58.

Benzinga · May 9, 2022